Statement on FDA’s request for information on requiring fixed-quantity blister packaging for certain opioid pain medicines to help decrease unnecessary exposure to opioids

May 30, 2019 – The opioid tragedy has become one of the defining public health crises of modern times. As the rates of opioid addiction and overdose continue to grow, addressing the opioid crisis has taken on more urgency. For the past few years, the U.S. Food and Drug Administration has been focusing on decreasing unnecessary exposure to prescription opioids as a way to prevent new addiction; supporting the treatment of those with opioid use disorder; promoting the … (leggi tutto)